Join Dr Alexander Cohen for a discussion of his study: Comparison of fatal or irreversible events with extended‐duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy
[template part=”video”]
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey[template part=”speaker”]
Topic
Patients who are hospitalised for acute medical illnesses are at an increased risk for venous thromboembolism. Betrixaban recently became the first NOAC to receive approval for extended-duration thromboprophylaxis after hospital discharge in this patient population. In this journal club, we take a look at the most recent post-hoc analysis to emerge from the APEX trial, which considers the impact of betrixaban on fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin.
View abstract access full paper
[template part=”details”]